BRUIN-CLL-314: A phase 3 trial of pirtobrutinib compared to ibrutinib in adults with chronic lymphocytic leukaemia

A phase 3 trial testing pirtobrutinib compared to ibrutinib in adults with chronic lymphocytic leukaemia.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05254743

Trial aim and background

The aim of this trial is to compare the efficacy and safety of using pirtobrutinib versus ibrutinib in adults with CLL/SLL. The trial could last up to six years.

Participants may or may not have already had treatment for their CLL/SLL.

Who can enter

Adults with CLL/SLL requiring treatment may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • Singleton Hospital, Swansea
  • Bristol Haematology and Oncology Centre, Bristol
  • Castle Hill Hospital, Hull
  • Leicester Royal Infirmary, Leicester
  • St Bartholomew's Hospital, London
  • City Hospital, Nottingham
  • Sunderland Royal Hospital, Sunderland

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT05254743 

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.